(R)(+)-N-Propargyl-1-aminoindan (rasagiline) and derivatives: highly selective and potent inhibitors of monoamine oxidase B
(+)-N-Propargyl-1-aminoindan (rasagiline) and a series of derivatives have been synthesized and screened for monoamine oxidase inhibitory activity. Rasagiline and several analogues were found be highly selective and potent inhibitors of the B form of the enzyme in contrast to the levorotatory enantiomer which was not active. The results indicate that rasagiline has potential for the treatment of Parkinson’s Disease. This compound is currently under development for that indication.
KeywordsMonoamine Oxidase Irreversible Inhibitor Parkinson Study Group Absolute Stereochemistry 1Teva Pharmaceutical Industry
Unable to display preview. Download preview PDF.
- Polymeropoulos E (1993) 1-Deprenyl: a unique MAO-B inhibitor. In: Szelenyi I (ed) Inhibitors of monoamine oxidase. Birkhäuser, Basel, pp 109–124Google Scholar
- Sterling J, Levy R, Veinberg A, Goldenberg W, Finberg J, Youdim MBH, Gutman A (1996) Monofluorinated derivatives of N-propargyl-1-aminoindan and their use as inhibitors of monoamine oxidase. USP 4, 486, 541Google Scholar
- Youdim MBH, Finberg J, Levy R, Sterling J, Lerner D, Berger-Peskin T, Yellin H (1995) R-Enantiomers of N-propargyl-aminoindan compounds, their preparation and pharmaceutical compositions containing them. USP 5, 457, 133Google Scholar